Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Financial Results:
Lupin Ltd reported Revenues for Q4FY24 of ₹4,961.00 Crores up from ₹4,430.00 Crore year on year, a rise of 11.99%.
Total Expenses for Q4FY24 of ₹4,492.00 Crores up from ₹4,209.00 Crores year on year, a rise of 6.72%.
Consolidated Net Profit of ₹368.00 Crores up 52.07% from ₹242.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.89, up 52.02% from ₹5.19 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.